PO.6.131 A randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303, a potent dual baff/april inhibitor, in adult healthy volunteers

• A Smith,
• P Harrison,
• S Peng,
• S Dillon,
• J Lickliter,
• K Manjarrez,
• M Lessig,
• R Sanderson,
• A Chunyk,
• H Zayed

Affiliations

A Smith

intensive care follow-up nurse

P Harrison

University of Oxford, Oxford, UK

S Peng

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA

S Dillon

2International Institute of Nutritional Sciences and Applied Food Safety Studies, College of Health & Wellbeing, University of Central Lancashire

J Lickliter

2Nucleus Network ~ Melbourne ~ Australia

K Manjarrez

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA

M Lessig

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA

R Sanderson

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA

A Chunyk

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA

H Zayed

1Alpine Immune Sciences, Inc. ~ Seattle ~ USA